Practice guidelines for breast cancer

Cancer Journal from Scientific American

Volumn 2, Issue 9999, 1996, Pages

  Love, Susan ^a   Parker, Barbara ^b   Ames, Margaret ^c   Taylor, Cat ^d   Gilden, Ron ^e   Figlin, Robert A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c IQ Solutions   (United States)

^d Preferred Oncol Networks of America   (United States)

^e CDP Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST TUMOR; CANCER STAGING; CLINICAL TRIAL; FEMALE; HUMAN; PATHOLOGY; PRACTICE GUIDELINE; REVIEW;

BREAST NEOPLASMS; CLINICAL TRIALS; FEMALE; HUMANS; NEOPLASM STAGING;

EID: 0002892071     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. National Cancer Institute. 1996 budget estimate for scientific opportunities. September 1994.
2. Seidman H, Stellman SD, Mushinski MH. A different perspective on breast cancer risk factors: some implications of the nonattributable risk. CA Cancer J Clin 1982;32(5):301.
3. American College of Obstetrics and Gynecology. Carcinoma of the breast. Int J Gynecol Obstet 1992;39:237-243.
4. Hamed H, Coady A, Chaudary M, Fentiman I. Follow-up of patients with aspirated breast cysts is necessary. Arch Surg 1989; 124:253.
5. Layfield LJ, Chrischilles E, Cohen M, Bottles K. The palpable breast nodule. Cancer 1993;72:1642.
6. Silverman J. Diagnostic accuracy, cost-effectiveness, and triage role of fine-needle aspiration biopsy in the diagnosis of palpable breast lesions. The Breast Journal 1995;1(1):3.
7. Martelli G, Pilotti S, de Yoldi GC et al. Diagnostic efficacy of physical examination, mammography, fine needle aspiration, cytology (triple-test) in solid breast lumps: An analysis of 1708 cases. Tumori 1990;76:476.
8. Fisher B, Costantino J, Redmond C, Fisher E et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Eng J Med 1993; 328(22): 1581-1586.
9. McGuire WL, Tandon AK, Allred DC, Chamness GC, Clark GM. How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 1990;82(12):1006-1015.
10. Stierer M, Rosen H, Weber R, Hanak H, Spona J, Tuchler H. Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Correlation of histopathology and prognostic factors. Ann Surg 1993;218(1): 13-21.
11. Davis BW, Gelber RD, Goldhirsch A, et al. Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer 1986;58(12):2662-2670.
12. Balch CM, Singletary SE, Bland KI. Clinical decision-making in early breast cancer. Ann Surg 1993;217(3):207-225.
13. Patchefsky AS, Schwartz GF, Finkelstein SA, et al. Heterogeneity of intraductal carcinoma of the breast. Cancer 1989;63(4): 731-741.
14. Fisher ER, Costantino J, Fisher B, Palekar AS, Redmond C, Mamounas E. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Cancer 1995;75:1310-1319.
15. Stotter AT, McNeese M, Oswald MJ, Ames FC, Romsdahl MM. The role of limited surgery with irradiation in primary treatment of ductal in situ breast cancer. Int J Radiat Oncol Biol Phys 1990;18(2):283-287.
16. Bornstein BA, Recht A, Connolly JE et al. Results of treating ductal carcinoma in situ of the breast with conservative surgery and radiation therapy. Cancer 1991;67(1):7-13.
17. McCormick B, Rosen PP, Kinne D, Cox E, Yahalom J. Duct carcinoma in situ of the breast: an analysis of local control after conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys 1991;21(2):289-292.
18. Silverstein MJ, Waisman JR, Gierson ED, Colburn W, Gamagami P, Lewinsky BS. Radiation therapy for intraductal carcinoma. Is it an equal alternative? Arch Surg 1991;126(4): 424-428.
19. Solin EJ, Recht A, Fourquet A et al. Ten-year results of breast-conserving surgery and definitive irradiation for intraductal carcinoma (ductal carcinoma in situ) of the breast. Cancer 1991; 68(11):2337-2344.
20. Orel SG, Troupin RH, Patterson EA, Fowble BE. Breast cancer recurrence after lumpectomy and irradiation: role of mammography in detection. Radiology 1992;183(1):201-206.
21. Frykberg ER, Santiago F, Betsill WL Jr, O'Brien PH. Lobular carcinoma in situ of the breast. [Review] Surg Gynecol Obstet 1987;164(3):285-301.
22. Ciatto S, Cataliotti L, Cardona G, Bianchi S. Risk of infiltrating breast cancer subsequent to lobular carcinoma in situ. The Coordinating Center and Writing Committee of FONCAM (National Task Force for Breast Cancer). Tumori 1992;78(4): 244-246.
23. Walt AJ, Simon M, Swanson GM. The continuing dilemma of lobular carcinoma in situ. Arch Surg 1992;127(8):904-7; discussion 907-909.
24. Osborne MP, Hoda SA. Current management of lobular carcinoma in situ of the breast. Oncology 1994;8(2):45-9; discussion 49, 53-54.
25. Fisher B, Redmond C, Wickerham DL et al. Doxorubicin-containing regimens for the treatment of stage II breast cancer: the national surgical adjuvant breast and bowel project experience. J Clin Oncol 1989;7(5):572-582.
26. Veronesi U, Luini A, Del Vecchio M et al. Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. New Engl J Med 1993;328(22):1587-1591.
27. Veronesi U, Salvadori B, Luini A, et al. Conservative treatment of early breast cancer. Long-term results of 1232 cases treated with quadrantectomy, axillary dissection, and radiotherapy. Ann Surg 1990;211(3):250-259.
28. Fowble B, ed. Conservative Management of Early-Stage Breast Cancer. Patterns of Care Study Newsletter 1990-1991;5:1-11.
29. Weiss MC, Fowble BE, Solin EJ, Yeh IT, Schultz DJ. Outcome of conservative therapy for invasive breast cancer by histologic subtype. Int J Radiat Oncol Biol Phys 1992;23(5):941-947.
30. Lichter AS, Lippman ME, Danforth DN Jr, et al. Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. J Clin Oncol 1992;10(6):976-983.
31. Holland R, Connolly JE, Gelman R et al. The presence of an extensive intraductal component following a limited excision correlates with prominent residual disease in the remainder of the breast. J Clin Oncol 1990;8(1):113-118.
32. Boyages J, Recht A, Connolly JL, et al. Early breast cancer: predictors of breast recurrence for patients treated with conservative surgery and radiation therapy. Radiother Oncol 1990;19(1): 29-41.
33. Zafrani B, Vielh P, Fourquet A et al. Value of the ductal in situ component and other pathological variables on local control and survival. Long-term results. Eur J Can Clin Oncol 1989;25(11): 1645-1650.
34. Vicini FA, Eberlein TJ, Connolly JL. The optimal extent of resection for patients with stages I or II breast cancer treated with conservative surgery and radiotherapy. Ann Surg 1991;214(3): 200-4; discussion 204-5.
35. Recht A, Pierce SM, Abner A et al. Regional nodal failure after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol 1991;9(6):988-996.
36. Auquier A, Rutqvist LE, Hst H, Rotstein S, Arriagada R. Postmastectomy megavoltage radiotherapy: the Oslo and Stockholm trials. Eur J of Can 1992;28(2-3):433-437.
37. Velez-Garcia E, Carpenter JT Jr, Moore M et al. Postsurgical adjuvant chemotherapy with or without radiotherapy in women with breast cancer and positive axillary nodes: a South-eastern Cancer Study Group (SEG) Trial. Eur J Can 1992;28A(11): 1833-1837.
38. Graversen HP, Blichert-Toft M, Andersen JA, Zedeler K. Breast cancer: risk of axillary recurrence in node-negative patients following partial dissection of the axilla. Eur J Surg Oncol 1988;14(5): 407-412.
39. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339:1-15, 71-85.
40. Fisher B, Slack N, Katrych D, Wolmark N. Ten-year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 1975;140(4):528-534.
41. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as a adjuvant treatment in operable breast cancer. N Engl J Med 1976;294(8):405-410.
42. Jones SE, Moon TE, Bonadonna G, et al. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base. Am J Clin Oncol 1987;10(5): 387-395.
43. Harness JK, Bartlett RH, Saran PA, Bord MA, Noble WC. Developing a comprehensive breast center. Am Surg 1987;53(8): 419-423.
44. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' adjuvant trial organisation. Br J Cancer 1988;57(6):608-11.
45. Fisher B, Redmond C, Wickerham DL et al. Doxorubicin-containing regimens for the treatment of stage II breast Cancer: the National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 1989;7(5):572-582.
46. Fisher B, Redmond C, Poisson R et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1989;320(13):822-828.
47. Fisher B, Redmond C, Dimitrov NV et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 1989;320(8): 473-478.
48. Fisher B, Costantino J, Redmond C et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320(8):479-484.
49. Fisher B, Redmond C, Wickerham L et al. Systemic therapy in patients with node-negative breast cancer. A commentary based on two National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials. Ann Intern Med 1989;111(9):703-712.
50. Mansour EG, Gray R, Shatila AH et al. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med 1989;320(8):485-490.
51. Fisher B, Brown AM, Dimkrov NV et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8(9):1483-1496.
52. Cascinelli N, Greco M. Bufalino R, Clemente C et al. Prognosis of breast cancer with axillary node metastases after surgical treatment only. Eur J Can Clin Oncol 1987;23(6):795-799.
53. Moot SK, Peters GN, Cheek JH. Tumor hormone receptor status and recurrences in premenopausal node negative breast carcinoma. Cancer 1987;60(3):382-385.
54. Rosen PP, Groshen S, Kinne DW. Prognosis in T2N0M0 stage I breast carcinoma: a 20-year follow-up study. J Clin Oncol 1991;9(9):1650-1661.
55. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63(1):181-187.
56. McGuire WL, Tandon AK, Allred DC, Chamness GC, Ravdin PM, Clark GM. Treatment decisions in axillary node-negative breast cancer patients. Nad Cancer Inst Monogr 1992;11: 173-180.
57. Fisher B, Redmond C, Brown A et al. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol 1986;4(4):459-471.
58. Davis BW, Gelber RD, Goldhirsch A et al. Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer 1986;58(12): 2662-2670.
59. Fisher B, Gunduz N, Costantino J et al. DNA flow cytometric analysis of primary operable breast cancer. Relation of ploidy and s-phase fraction to outcome of patients in NSABP B-04. Cancer 1991;68(7):1465-1475.
60. Sigurdsson H, Baldetorp B, Borg A et al. Indicators of prognosis in node-negative breast cancer. N Engl J Med 1990; 322(15): 1045-1053.
61. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary node-negative breast cancer. N Engl J Med 1992;326:1756-1761.
62. Clark GM, Mathieu M, Owens, MA et al. Prognostic significance of s-phase fraction in good-risk, node-negative breast cancer patients. J Clin Oncol 1992;10(3):428-432.
63. Muss HB, Thor AD, Berry DA et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer [see comments] N Engl J Med 1994;330:1260-1266. [published erratum appears in N Engl J Med 1994 Jul 21;331(3):211.]
64. Gusterson BA, Gelber RD, Goldhirsch A et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992;10(7): 1049-1056.
65. Paik S, Hazan R, Fisher EF et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbb-2 protein overexpression in primary breast cancer. J Clin Oncol 1990;8(1):103-112.
66. Toikkanen S, Helin H, Isola J, Joensuu H. Prognostic significance of her-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clinl Oncol 1992;10(7):1044-1048.
67. Berns EM, Klijn JG, van Putten WL, van Staveren IL, Portengen H, Fockens JA. C-myc amplification is a better prognostic factor than her2/neu amplification in primary breast cancer. Cancer Res 1992;52(5):1107-1113.
68. Gasparini G, Weidner N, Bevilacqua P et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994;12(3):454-466.
69. Tancini G, Bonadonna G, Valagussa P, Marchini S, Veronesi U. Adjuvant CMP in breast cancer: comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1983;1(1):2-10.
70. Buzdar AU, Kau SW, Smith TL, Hortobagyi GN. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol 1989;12(2):123-128,.
71. Sener SF, Imperato JP, Khandekar JD Ragin A, Beck J, Merkel DE. Achieving local control for inflammatory carcinoma of the breast. Surg Gynecol Obstet 1992;175(2):141-144.
72. Shpall EJ, Jones RB, Bearman S. High-dose therapy with autologous bone marrow transplantation for the treatment of solid tumors. Curr Opin Oncol 19XX;6(2):135-138.
73. Kennedy MJ, Beveridge RA, Rowley SD, Gordon GB, Abeloff MD, Davidson NE. High-dose chemotheraphy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 1991;83(13):920-926.
74. Wong K, Henderson IC. Management of metastatic breast cancer. World J Surg 1994;18(1):98-111.
75. American Joint Committee on Cancer. Manual for Staging of Cancer. 4th ed. Philadelphia:J.B. Lippincott Co., 1992.
76. Moore MP, Ihde JK, Crowe JP Jr, Hakes TP, Kinne DW. Inflammatory breast cancer. Arch Surg 1991;126(3):304-306.
77. Perry MC, Kardinal CG, Korzun AH et al. Chemohormonal therapy in advanced carcinoma of the breast: Cancer and Leukemia Group B Protocol 8081. J Clin Oncol 1987; 5(10): 1534-1545.
78. Tannock IF. Treating the patient, not just the cancer. N Engl J Med 1987;317(24):1534-1535.
79. Smalley RV, Lefante J, Bartolucci A, Carpenter J, Vogel C, Krauss S. A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (caf) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (cmfvp) in patients with advanced breast cancer. Breast Cancer Res Treat 1983;3(2):209-220.
80. Tranum BL, McDonald B, Thigpen T et al. Adriamycin combinations in advanced breast cancer. A Southwest Oncology Group Study. Cancer 1982;49(5):835-839.
81. Mignot L, Morvan F, Berdah J et al. [Pregnancy after treated breast cancer. Results of a case-control study]. [French] Presse 1986;Medicale 15(39):1961-1964.
82. Doll DC, Ringenberg QS, Yarbro JW. Antineoplastic agents and pregnancy. Semin Oncol 1989;16(5):337-346.
83. Garber JE. Long-term follow-up of children exposed in utero to antineoplastic agents. Semin Oncol 1989;16(5):437-444.
84. Barber RK. The gynecologist and breast disease. Eur J Gynaecol Oncol 1992;13(1):5-16.
85. Redmond XX. Physiological changes during pregnancy and their implications for pharmacologic treatment. Clin Invest Med 1985;8:317-322.
86. Sutcliffe SB. Treatment of neoplastic disease during pregnancy: maternal and fetal effects. Clin Invest Med 1985;8(4):333-338.
87. Reichman XX, Green XX. Breast cancer in young women: effect of chemotherapy on ovarian function, fertility, and birth defects. Natl Cancer Inst Monograph.
88. Turchi JJ, Villasis C. Anthracyclincs in the treatment of malignancy in pregnancy. Cancer 1988;61(3):435-440.
89. Petrek JA, Dukoff R. Rogatko A. Prognosis of pregnancy-associated breast cancer. Cancer 1991;67(4):869-872.
90. Cummings FJ, Glicksman AS, Wanebo HJ. Breast cancer management in the nineteen nineties. Rhode Island Med 1992; 75(1):21-29.
91. Balducci L, Schapira DV, Cox CR, Greenberg HM, Lyman GH. Breast cancer of the older woman: an annotated review. J Am Geriatr Soc 1991;39(11):1113-1123.
92. Cummings FJ, Gray R, Tormey DC et al. Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer long-term follow-up and causes of death. J Clin Oncol 1993; 11(1):29-35.
93. Taylor SG, Knuiman MW, Sleeper LA et al. Six-year results of the Eastern Cooperative Oncology Group trial of observation versus CMFP versus CMFPT in postmenopausal patients with node-positive breast cancer. J Clin Oncol 1989;7(7):879-889.
94. Claus RB, Risch N, Thompson WD. Autosomal dominant inheritance of carry-onset breast cancer. Implications for risk prediction. Cancer 1994;73(3):643-651.
95. Gail MH, Brin ton LA, Byar DP et al. Protecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81(24): 1879-1886.
96. Miki Y, Swensen J, Shattuck-Ridens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266(5182):66-71.
97. Wooster R, Neuhausen SL, Mangion J et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994;265(5181):2088-2090.
98. Buzzoni R, Bonadonna G, Valagussa P, Zambetti M. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fltiorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol 1991;9(12): 2134-2140.
99. Tormey DC, Gray R, Abeloft MD et al. Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1992;10(12):1848-1856.
100. Wood WC, Budman DR, Korzun AH et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma [see comments] [published erratum appears in New Engl J Med 1994 Jul 14;331(2):139]. N Engl J Med 1994;330(18):1253-1259.
101. Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986;4(8): 1162-1170.
102. Fisher B, Brown A, Wolmark N et al. Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. Ann Intern Med 1987;106(5):649-654.
103. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London. Lancet 1993;341(8856): 1293-1298.